News archive
The same industry news carried on our social channels, kept here in full and in date order. Each entry links to its primary source — a regulator, a journal, a legislature or the reporting outlet that broke it.
28 updates · newest first
Nasdaq-listed Psyence Biomedical established a Texas subsidiary to centralise US ibogaine supply, manufacturing, regulatory documentation and any future IND filing. Subject to licensing, the entity would hold US rights to PsyLabs pharmaceutical-grade ibogaine, signalling how listed companies are structuring around US policy momentum.
Psyence BioMed
Interviewing Americans for Ibogaine CEO Bryan Hubbard on his HHS podcast, the Health Secretary said demand — starting with veterans, at roughly 100 hours of support staff per patient — will surge once treatments are legal, and credited Trump's April executive order with breaking down barriers to evidence-based research.
Marijuana Moment
Rhelion Life Sciences has announced that Filament Health is planning a stability programme for botanical drug candidate IBEX011. Demonstrating product stability is an essential regulatory requirement before naturally derived ibogaine formulations can proceed into formal clinical development.
TMX Newsfile
A high-profile podcast appearance by the US health secretary pushed ibogaine further into public view, prompting a review of the underlying evidence base. The analysis is a reminder that attention is not data: cardiac risk and the absence of completed pivotal trials still frame the investment case.
TrialSite News
A JAMA Network Open trial found psilocybin plus structured therapy increased cocaine-abstinent days and complete abstinence versus active placebo. It is adjacent rather than ibogaine evidence, but it strengthens the wider thesis that single-dose psychedelic protocols can treat stimulant dependence.
PsyPost
Forbes has published an analysis examining the clinical significance of ibogaine treatments demonstrating therapeutic efficacy lasting up to one year. Long-term durability is critical for commercial positioning and regulatory evaluation, offering substantial health economic advantages over daily psychiatric drugs.
Forbes
We Are The Mighty profiles the VETS co-founder whose husband, a Navy SEAL, recovered after ibogaine and 5-MeO-DMT treatment abroad. VETS advocacy remains one of the strongest drivers of US political and funding support for supervised ibogaine care.
We Are The Mighty
Barrow Neurological Institute and Arizona State University are embarking on one of the first US-based ibogaine clinical trials. The study provides crucial institutional validation and safety data required to advance ibogaine towards formal FDA approval and domestic clinical adoption.
ASU News
The government of Gabon is acting to reclaim sovereignty over domestic iboga supplies as worldwide commercial interest accelerates. Securing ethical supply chains and adhering to the Nagoya Protocol represent critical risk factors for pharmaceutical developers relying on naturally sourced botanical material.
pulitzercenter.org
The University of Miami has transferred its historic 1994 Investigational New Drug application for ibogaine to the US Department of Health and Human Services. Releasing these foundational regulatory files into the public domain reduces barriers and compliance costs for researchers and drug developers.
Yahoo Finance
MAPS — which funded the original University of Miami programme in the 1990s — welcomed the gift of the 1994 investigational new drug application to HHS, while cautioning that a 30-year-old IND is not a substitute for current cardiac safety and sourcing data.
MAPS
The Arizona Department of Health Services funded a five-year clinical trial of ibogaine for traumatic brain injury and related neurological conditions, with first enrolment expected in 2027 — a second US state now paying for ibogaine science directly.
Barrow Neurological Institute / KJZZ
Announced by the President, the university handed over its drug application so ibogaine can move into US clinical trials under the April executive order and expanded right-to-try access — removing one of the last procedural blocks to formal trials.
Just The News / Military.com
Translational Psychiatry published long-term follow-up of the Stanford MISTIC protocol, reporting that improvements in disability, PTSD, depression and anxiety were largely sustained a year after a single treatment.
Translational Psychiatry (Nature)
Special Notice ARPA-H-SN-26-158 seeks teams to run safe, rapid clinical evaluation of ibogaine in opioid use disorder — federal money moving from policy into trial infrastructure, with sourcing and monitoring capability central to selection.
ARPA-H (via Everglade Consulting)
A private US research institute submitted its own investigational new drug application for pharmaceutical-grade ibogaine hydrochloride — evidence that GMP-grade supply, not enthusiasm, is now the rate-limiting step.
Scottsdale Research Institute
A general-audience review of where ibogaine sits in PTSD treatment, covering reported outcomes alongside the cardiac screening and supervision requirements. Mainstream health coverage of this kind is widening the referral and investor audience.
Preferred Health Magazine
The two departments announced a comprehensive partnership to move psychedelic-assisted therapies, ibogaine included, through evaluation and into veteran care pathways — the delivery arm of April's executive order.
US Department of Health and Human Services
A bipartisan bill would have the state health department stand up an interstate pilot programme for ibogaine research for veterans — a third US state legislature putting appropriations behind the compound.
MLive
Three patients with persistent post-concussive and hypoxic brain injury symptoms improved on a combined iboga microdosing and psychotherapy protocol. A case series is not proof of efficacy, but it points at the microdosing layer now attracting commercial interest.
Frontiers in Pharmacology
Episode 2477 puts the Texas ibogaine programme architects in front of a mass audience, focusing on veterans, first responders and brain health. Podcast reach of this scale has repeatedly preceded state-level funding decisions.
The Joe Rogan Experience
A feature on veteran trials notes strong signals for treatment-resistant PTSD alongside an unresolved mechanism of action — and an unresolved cardiac risk profile that keeps medical screening non-negotiable.
BBC Future
Days after the executive order, the FDA awarded priority review vouchers to two psilocybin developers and one MDMA developer — the clearest signal yet that a regulatory pathway for this class is opening.
AP News
Former Governor Rick Perry said Texas anticipates a share of the $50m in federal funding attached to the order, layered onto state money already allocated to ibogaine trials for veterans.
Houston Chronicle
Executive Order 14401 directs the FDA and federal agencies to accelerate review of psychedelics including ibogaine. Rogan, a long-time ibogaine advocate, joined the signing and recounted texting the President about it.
AP News / Al Jazeera
After no pharmaceutical proposal met the legislature's standards, Texas said it would fund and run the research itself with statewide medical researchers — a state-led route to FDA data.
The Texas Tribune
A synthetic route to ibogaine removes dependence on wild-harvested Tabernanthe iboga root bark. Synthesis is central to the supply question that constrains every clinical and commercial programme in the field.
SciTechDaily
Clearmind announced notice of an international patent application covering a combination therapy involving ibogaine. Patent filings mark where defensible commercial positions are being staked in a field otherwise built on an unpatentable natural molecule.
Clearmind Medicine
We post these updates as they land on X, Meta and LinkedIn, and cover the New Zealand angle in more depth on the main site.